TickerFacts.

Akebia Therapeutics, Inc. (AKBA): Total Liabilities

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the years ended 2017-12-31, 2021-12-31 (for example after a spin-off or a discontinued operation), while the year before each was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$343.95M
As of 2025-12-31
$324.64M
As of 2026-06-30
-0.7%
3-year compound annual growth
$519.22M2013-12-31: $3.91M2014-12-31: $6.92M2015-12-31: $11.94M2016-12-31: $232.10M2017-12-31: $241.67M2018-12-31: $360.61M2019-12-31: $376.44M2020-12-31: $396.52M2021-12-31: $455.34M2022-03-31: $519.22M2022-06-30: $470.95M2022-09-30: $435.99M2022-12-31: $350.82M2023-12-31: $272.29M2024-12-31: $269.86M2025-12-31: $343.95M$343.95M
2013-12-31 Total Liabilities (USD) 2025-12-31
Period endedTotal LiabilitiesChange YoYSource filing
2025-12-31$343.95M+27.5%2026-02-26, Balance as of period end
2024-12-31$269.86M-0.9%2026-02-26, Balance as of period end
2023-12-31$272.29M-22.4%2025-03-13, Balance as of period end
2022-12-31$350.82Mn/a2024-03-14, Balance as of period end
2022-09-30$435.99Mn/a2023-08-28, Balance as of period end
2022-06-30$470.95Mn/a2023-08-28, Balance as of period end
2022-03-31$519.22Mn/a2023-08-28, Balance as of period end
2021-12-31$455.34Mn/c2023-08-28, Balance as of period end
2020-12-31$396.52M+5.3%2022-03-01, Balance as of period end
2019-12-31$376.44M+4.4%2021-02-25, Balance as of period end
2018-12-31$360.61M+49.2%2020-03-12, Balance as of period end
2017-12-31$241.67Mn/c2019-03-26, Balance as of period end
2016-12-31$232.10Mn/m2018-03-12, Balance as of period end
2015-12-31$11.94M+72.6%2017-03-06, Balance as of period end
2014-12-31$6.92M+76.9%2016-03-14, Balance as of period end
2013-12-31$3.91Mn/a2015-03-04, Balance as of period end

Total Liabilities at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedTotal LiabilitiesChange YoY
Akebia Therapeutics, Inc. (AKBA)2025-12-31$343.95M+27.5%
Keros Therapeutics, Inc. (KROS)2025-12-31$34.89M-21.3%
Puma Biotechnology, Inc. (PBYI)2025-12-31$85.96M-29.1%
IDEAYA Biosciences, Inc. (IDYA)2025-12-31$86.39M+33.0%
Schrodinger, Inc. (SDGR)2025-12-31$362.11M-9.9%
Vanda Pharmaceuticals Inc. (VNDA)2025-12-31$161.76M+37.5%
Amarin Corp PLC (AMRN)2025-12-31$211.49M+6.2%
Arvinas, Inc. (ARVN)2025-12-31$284.00M-46.4%
Ligand Pharmaceuticals Inc (LGND)2025-12-31$543.42M+388.1%

Compare AKBA, KROS, PBYI, IDYA side by side · Screen every company in Pharmaceutical Preparations ↗